Syneos Health Names Terttu Haring President, Clinical Sites & Patients
26 September 2023 - 9:30PM
Syneos Health® (Nasdaq: SYNH), a leading fully integrated
biopharmaceutical solutions organization, has announced the
appointment of Terttu Haring, MD, as President, Clinical Sites
& Patients. With nearly 30 years of experience, Dr. Haring will
lead the global clinical operations organization to drive
exceptional delivery, quality and data integrity for customers,
while ensuring a positive experience for sponsors, sites and
patients. Her investigator background, and technology and data
experience, will empower the Clinical Sites & Patients team to
execute data-driven solutions that produce strong results for
customers.
Under Dr. Haring’s guidance, Syneos Health will continue to
nurture its heritage of scientific and therapeutic expertise across
global clinical operations. Dr. Haring will also empower the
Clinical Sites & Patients team to leverage the Company’s
in-depth local regulatory experience, with its expanding global
footprint, to better connect patients and sites worldwide. Fueled
by advanced data, analytics and insights from sources such as
Syneos Health’s Patient Voice Consortium, the team is leveraging
technology and deep enterprise expertise to execute more
representative clinical trial research.
Based in Amsterdam, Netherlands, Dr. Haring’s appointment adds
to a growing team of global therapeutic experts at Syneos Health
who design and execute fit-for-purpose solutions that deliver
high-quality results for customers across the clinical to
commercial continuum.
“As the clinical trial landscape rapidly evolves, a steadfast
focus on designing the best protocols, enabling sites and site
networks, and empowering patients is key for successful clinical
trial execution and product commercialization,” said Michael
Brooks, Chief Operating Officer, Syneos Health. “We are thrilled to
welcome Terttu to our organization to help us advance our operating
model to more effectively execute clinical operations that meet
industry, customer, partner and patient needs. Her relentless focus
on execution and quality will continue to build our
patient-centered clinical trial solutions that enable sponsors to
accelerate the development of treatments that impact patients’
lives.”
With decades of pharma and CRO experience, Dr. Haring most
recently held multiple leadership roles at Sanofi, with escalating
responsibility across Clinical Research, Trial Operations and Data
Management, and Clinical Innovation. She began her research career
at Kendle International, a CRO acquired by INC Research, which then
became Syneos Health.
“I am passionate about unlocking the potential of clinical
trials for all patients – leveraging digital health, data science
and site productivity enhancements for optimized operations,” said
Dr. Haring. “I look forward to leveraging Syneos Health’s vast
enterprise to deliver for sponsors and bring patients and sites
more actively together – meeting and anticipating the needs of all
stakeholders in the clinical trial ecosystem.”
About Syneos HealthSyneos Health® (Nasdaq:SYNH)
is a leading fully integrated biopharmaceutical solutions
organization built to accelerate customer success. We translate
unique clinical, medical affairs and commercial insights into
outcomes to address modern market realities.
We bring together a talented team of professionals, who work
across more than 110 countries, with a deep understanding of
patient and physician behaviors and market dynamics. Together
we share insights, use the latest technologies and apply advanced
business practices to speed our customers’ delivery of important
therapies to patients.
Syneos Health supports a diverse, equitable and inclusive
culture that cares for colleagues, customers, patients, communities
and the environment.
To learn more about how we are Shortening the distance
from lab to life®, visit
syneoshealth.com.
Investor Relations Contact: |
Press/Media Contact: |
Ronnie Speight |
Gary Gatyas |
Senior Vice President, Investor Relations |
Executive Director, External Communications |
+1 919 745 2745 |
+1 908 763 3428 |
Investor.Relations@syneoshealth.com |
gary.gatyas@syneoshealth.com |
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jan 2025 to Feb 2025
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Feb 2024 to Feb 2025